Form 4: Phathom Pharmaceuticals Director Frank Karbe Reports Stock Transaction
SEC Form 4 Filing
Director Frank Karbe reports acquisition and disposition of Phathom Pharmaceuticals (PHAT) common stock.
Summary
- On May 29, 2024, Frank Karbe, a director of Phathom Pharmaceuticals, acquired 25,000 shares of common stock at a price of $10.1645 per share.
- Following this transaction, Karbe disposed of 44,500 shares.
- The reported price is a weighted average, with sales occurring between $10.1016 and $10.20.
- Karbe has undertaken to provide full information regarding the number of shares sold at each separate price within that range upon request.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing a stock transaction by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, helping investors understand their trading activities and potential sentiment regarding the company's stock.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as it can provide insights into management's perspective on the company's value and future prospects.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of stock transaction: acquisition of 25,000 shares and disposition of 44,500 shares. |
| 05/31/2024 | Date of signature by Attorney-in-Fact for Frank Karbe. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.